|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yu SJ: A concise review of updated
guidelines regarding the management of hepatocellular carcinoma
around the world: 2010–2016. Clin Mol Hepatol. 22:7–17. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Poon D, Anderson BO, Chen LT, Tanaka K,
Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, et al:
Asian Oncology Summit: Management of hepatocellular carcinoma in
Asia: Consensus statement from the Asian Oncology Summit 2009.
Lancet Oncol. 10:1111–1118. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bellissimo F, Pinzone MR, Cacopardo B and
Nunnari G: Diagnostic and therapeutic management of hepatocellular
carcinoma. World J Gastroenterol. 21:12003–12021. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Flores A and Marrero JA: Emerging trends
in hepatocellular carcinoma: Focus on diagnosis and therapeutics.
Clin Med Insights Oncol. 8:71–76. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Petrick JL, Kelly SP, Altekruse SF,
McGlynn KA and Rosenberg PS: Future of hepatocellular carcinoma
incidence in the united states forecast through 2030. J Clin Oncol.
34:1787–1794. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Han KQ, He XQ, Ma MY, Guo XD, Zhang XM,
Chen J, Han H, Zhang WW, Zhu QG, Nian H, et al: Inflammatory
microenvironment and expression of chemokines in hepatocellular
carcinoma. World J Gastroenterol. 21:4864–4874. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moschen AR, Fritz T, Clouston AD, Rebhan
I, Bauhofer O, Barrie HD, Powell EE, Kim SH, Dinarello CA,
Bartenschlager R, et al: Interleukin-32: A new proinflammatory
cytokine involved in hepatitis C virus-related liver inflammation
and fibrosis. Hepatology. 53:1819–1829. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Felaco P, Castellani ML, De Lutiis MA,
Felaco M, Pandolfi F, Salini V, De Amicis D, Vecchiet J, Tete S,
Ciampoli C, et al: IL-32: A newly-discovered proinflammatory
cytokine. J Biol Regul Homeost Agents. 23:141–147. 2009.PubMed/NCBI
|
|
11
|
Jeong HJ, Shin SY, Oh HA, Kim MH, Cho JS
and Kim HM: IL-32 up-regulation is associated with inflammatory
cytokine production in allergic rhinitis. J Pathol. 224:553–563.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim S: Interleukin-32 in inflammatory
autoimmune diseases. Immune Netw. 14:123–127. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Khawar MB, Abbasi MH and Sheikh N: IL-32:
A novel pluripotent inflammatory interleukin, towards gastric
inflammation, gastric cancer, and chronic rhino sinusitis.
Mediators Inflamm. 2016:84137682016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Park JS, Choi SY, Lee JH, Lee M, Nam ES,
Jeong AL, Lee S, Han S, Lee MS, Lim JS, et al: Interleukin-32β
stimulates migration of MDA-MB-231 and MCF-7 cells via the
VEGF-STAT3 signaling pathway. Cell Oncol. 36:493–503. 2013.
View Article : Google Scholar
|
|
15
|
Zeng Q, Li S, Zhou Y, Ou W, Cai X, Zhang
L, Huang W, Huang L and Wang Q: Interleukin-32 contributes to
invasion and metastasis of primary lung adenocarcinoma via
NF-kappaB induced matrix metalloproteinases 2 and 9 expression.
Cytokine. 65:24–32. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang S, Chen F and Tang L: IL-32 promotes
breast cancer cell growth and invasiveness. Oncol Lett. 9:305–307.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ghaffari A, Hoskin V, Szeto A, Hum M,
Liaghati N, Nakatsu K, LeBrun D, Madarnas Y, Sengupta S and Elliott
BE: A novel role for ezrin in breast cancer
angio/lymphangiogenesis. Breast Cancer Res. 16:4382014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu X, Guo X, Li H, Chen J and Qi X:
Src/STAT3 signaling pathways are involved in KAI1-induced
downregulation of VEGF-C expression in pancreatic cancer. Mol Med
Rep. 13:4774–4778. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Galun E: Liver inflammation and cancer:
The role of tissue microenvironment in generating the
tumor-promoting niche (TPN) in the development of hepatocellular
carcinoma. Hepatology. 63:354–356. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen Q, Carroll HP and Gadina M: The
newest interleukins: Recent additions to the ever-growing cytokine
family. Vitam Horm. 74:207–228. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim SH, Han SY, Azam T, Yoon DY and
Dinarello CA: Interleukin-32: A cytokine and inducer of TNFalpha.
Immunity. 22:131–142. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nishida A, Andoh A, Inatomi O and Fujiyama
Y: Interleukin-32 expression in the pancreas. J Biol Chem.
284:17868–17876. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Heinhuis B, Koenders MI, Van den Berg WB,
Netea MG, Dinarello CA and Joosten LA: Interleukin 32 (IL-32)
contains a typical α-helix bundle structure that resembles focal
adhesion targeting region of focal adhesion kinase-1. J Biol Chem.
287:5733–5743. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Heinhuis B, Netea MG, Van den Berg WB,
Dinarello CA and Joosten LA: Interleukin-32: A predominantly
intracellular proinflammatory mediator that controls cell
activation and cell death. Cytokine. 60:321–327. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ishigami S, Arigami T, Uchikado Y,
Setoyama T, Kita Y, Sasaki K, Okumura H, Kurahara H, Kijima Y,
Harada A, et al: IL-32 expression is an independent prognostic
marker for gastric cancer. Med Oncol. 30:4722013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tsai CY, Wang CS, Tsai MM, Chi HC, Cheng
WL, Tseng YH, Chen CY, Lin CD, Wu JI, Wang LH, et al:
Interleukin-32 increases human gastric cancer cell invasion
associated with tumor progression and metastasis. Clin Cancer Res.
20:2276–2288. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yousif NG, Al-Amran FG, Hadi N, Lee J and
Adrienne J: Expression of IL-32 modulates NF-κB and p38 MAP kinase
pathways in human esophageal cancer. Cytokine. 61:223–227. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kang YH, Park MY, Yoon DY, Han SR, Lee CI,
Ji NY, Myung PK, Lee HG, Kim JW, Yeom YI, et al: Dysregulation of
overexpressed IL-32α in hepatocellular carcinoma suppresses cell
growth and induces apoptosis through inactivation of NF-κB and
Bcl-2. Cancer Lett. 318:226–233. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu K, Min XL, Peng J, Yang K, Yang L and
Zhang XM: The changes of HIF-1α and VEGF expression after TACE in
patients with hepatocellular carcinoma. J Clin Med Res. 8:297–302.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsuchiya K, Asahina Y, Matsuda S, Muraoka
M, Nakata T, Suzuki Y, Tamaki N, Yasui Y, Suzuki S, Hosokawa T, et
al: Changes in plasma vascular endothelial growth factor at 8 weeks
after sorafenib administration as predictors of survival for
advanced hepatocellular carcinoma. Cancer. 120:229–237. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nold-Petry CA, Nold MF, Zepp JA, Kim SH,
Voelkel NF and Dinarello CA: IL-32-dependent effects of IL-1beta on
endothelial cell functions. Proc Natl Acad Sci USA. 106:pp.
3883–3888. 2009; View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nold-Petry CA, Rudloff I, Baumer Y, Ruvo
M, Marasco D, Botti P, Farkas L, Cho SX, Zepp JA, Azam T, et al:
IL-32 promotes angiogenesis. J Immunol. 192:589–602. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hoshida Y, Fuchs BC and Tanabe KK:
Prevention of hepatocellular carcinoma: Potential targets,
experimental models, and clinical challenges. Curr Cancer Drug
Targets. 12:1129–1159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Welker MW and Trojan J: Antiangiogenic
treatment in hepatocellular carcinoma: The balance of efficacy and
safety. Cancer Manag Res. 5:337–347. 2013.PubMed/NCBI
|
